UNIVERSITY OF WASHINGTON

A study in *Frontiers in Psychology* validates BrainCheck Assess™ as a reliable digital cognitive assessment, showing strong correlation with the Montreal Cognitive Assessment (MoCA). BrainCheck Assess offers detailed cognitive analysis, integrates with EHR systems, and supports comprehensive cognitive care, enhancing patient monitoring and care planning.

A study in Frontiers in Psychology confirms BrainCheck Assess™'s reliability and accuracy in cognitive assessments, comparable to the Montreal Cognitive Assessment (MoCA). BrainCheck Assess™, an FDA Class II device, offers detailed cognitive domain analysis and integrates with EHR systems, enhancing patient care through precise digital cognitive health assessments.

Dr. Jake Berchuck discusses a novel epigenomic liquid biopsy platform for determining PSMA expression in prostate cancer, showing strong correlation with PSMA PET scan results. The platform analyzes cell-free DNA to infer tumor PSMA expression, potentially guiding treatment decisions for cell surface-targeting therapies and offering genome-wide insights into gene regulation.

Neurology departments implement new protocols to manage anti-amyloid monoclonal antibodies for dementia, addressing patient demand and optimizing care delivery through interdisciplinary collaboration and innovative staffing models.

The AAAI-24 Workshop Program, sponsored by the Association for the Advancement of Artificial Intelligence, features a series of workshops focusing on various AI topics. Key workshops include discussions on Large Language Models (LLMs) causality, AI for credible elections, digital human creation, AI in education, finance for social impact, AI in science and engineering, AI-based planning for cyber-physical systems, brain encoding and decoding with AI, cybersecurity, operations research, time series analysis, cognitive and mental health, neuro-symbolic learning, privacy-preserving AI, public sector LLMs, recommendation ecosystems, responsible language models, and scientific document understanding. Each workshop aims to bring together researchers and practitioners to discuss advancements, challenges, and applications in their respective fields.

Daniel Carson, MD, MS, discusses findings from the 'Telehealth visit type and patient-reported outcomes among patients with cancer' study, highlighting high patient satisfaction with both telehealth and in-person visits, and significantly higher costs and travel burdens associated with in-person visits, especially for new patients.

Neuralink's Blindsight, a visual prosthesis, has been designated a breakthrough device by the FDA, potentially expediting its approval. The technology aims to restore vision by directly stimulating neurons in the visual cortex, though it faces challenges and skepticism from experts. Elon Musk's ambitious claims about Blindsight's capabilities have raised expectations, but experts caution that the device is more likely to provide assistive technology rather than restore natural vision. The device's success hinges on completing full clinical trials and overcoming financial and technical hurdles.

A $2.5 million NIH award unites OHSU's ORPRN and WWAMI's WPRN to form a primary care research hub in the Pacific Northwest, aiming to enhance research-to-clinic connectivity and health equity. The PRaCTICE Network Research Hub will support innovative study designs addressing common health issues, with a focus on rural and underrepresented communities.

Dr. John Fortney discusses pragmatic trials, hybrid-effectiveness implementation trials, and their distinctions. He emphasizes the importance of practical implementation strategies and provides guidelines for choosing trial types, highlighting the need for clarity in research objectives.